Binge Eating Disorder (BED) Clinical Trial
— F-EATOfficial title:
Feedback Versus no Feedback to Improve Patient Outcome in Group Psychotherapy for Eating Disorders: A Randomised Clinical Trial
The current trial aims to investigate the impact of continuous feedback on dropout and outcome in group therapy. The hypothesis is that continuous feedback to patient and therapist on treatment progress and alliance will 1) increase adherence and 2) increase treatment outcome.
Status | Active, not recruiting |
Enrollment | 159 |
Est. completion date | December 2014 |
Est. primary completion date | August 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Aged 18 or older. - BMI of minimum 20. - Meet the diagnostic criteria for Bulimia Nervosa, Binge Eating Disorder or EDNOS according to DSM- IV. Exclusion Criteria: - Acute suicidal risk. - Psychosis. - Severe depression. - Abuse of alcohol, medicine and/or narcotics up to 3 months before referral. - Use of cannabis once a month is accepted at intake but must stop during treatment. - Concomitant psychotherapeutic/ psychiatric treatment outside Stolpegaard Psychotherapy Centre. - Severe or non-regulated physical co-morbidity. - Pregnancy. - Unable to understand Danish. - Previous participation in the current trial. - Considered unable to attend treatment sessions as planned. - Lack of informed consent. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Denmark | Stolpegaard Psychotherapy Centre | Gentofte |
Lead Sponsor | Collaborator |
---|---|
Marianne Lau, MD, DSci. | The Ministry of Science, Technology and Innovation, Denmark |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Self-Harm Inventory | At end of treatment? Participants will be followed for the duration of treatment, an expected average of 20 weeks. | Yes | |
Other | Outcome Rating Scale | At start of treatment and during treatment. Participants will be followed for the duration of treatment, an expected average of 20 weeks. | No | |
Other | Symptom Check List-90R | At start of treatment and during treatment. Participants will be followed for the duration of treatment, an expected average of three years. | No | |
Other | Sheehan Disability Scale | At start of treatment and during treatment. Participants will be followed for the duration of treatment, an expected average of three years. | No | |
Other | WHO-Five Well-being Index | At start of treatment and during treatment. Participants will be followed for the duration of treatment, an expected average of three years. | No | |
Primary | Adherence | Treatment adherence in the intervention period defined as a rate, i.e., number of attended therapy sessions divided by the number of planned therapy sessions. If a patient ends therapy prematurely, and this is in accordance with the therapists, the number of attended sessions will be set equal to the planned number of sessions. | At end of treatment. Participants will be followed for the duration of treatment, an expected average of 20 weeks. | No |
Secondary | Eating Disorders Examination Interview | At intake, end of treatment and follow-up. Participants will be followed for the duration of treatment and follow-up, an expected average of 3 years. | No |